Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 6/20 | 0.49 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.49 |
| ▸ | DPP4 | P27487 | 2/20 | 0.46 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.46 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.46 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.46 |
| ▸ | FAP | Q12884 | 1/20 | 0.46 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.43 |
| ▸ | ECE1 | P42892 | 2/20 | 0.41 |
| ▸ | ACE | P12821 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29590449 | 1.00 | MME (0.49) | MMETGFBR1DPP4DPP8DPP9 | |
| SCHEMBL29868562 | 1.00 | MME (0.49) | MMETGFBR1DPP4DPP8DPP9 | |
| SCHEMBL29630533 | 1.00 | MME (0.49) | MMETGFBR1DPP4DPP8DPP9 | |
| SCHEMBL6674368 | 0.96 | TGFBR1 (0.52) | MMETGFBR1DPP4DPP8DPP9 | |
| SCHEMBL28124001 | 0.96 | TGFBR1 (0.52) | MMETGFBR1DPP4DPP8DPP9 | |
| SCHEMBL31630525 | 0.90 | MME (0.55) | MMETGFBR1DPP4DPP8DPP9 | |
| SCHEMBL3289560 | 0.90 | MME (0.55) | MMETGFBR1DPP4DPP8DPP9 | |
| SCHEMBL3289576 | 0.90 | MME (0.55) | MMETGFBR1DPP4DPP8DPP9 | |
| SCHEMBL30930167 | 0.90 | MME (0.51) | MMEDPP4DPP8DPP9DPP7 | |
| SCHEMBL29462928 | 0.90 | DPP4 (0.43) | MMETGFBR1DPP4DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250011367-A1 | CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF | ENTRADA THERAPEUTICS, INC. | 2025-01-09 | — | — | US | disclosed |
| US-20220177523-A1 | CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF | ENTRADA THERAPEUTICS, INC. | 2022-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250011367-A1 | CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF | VIP, LNPEP, TAP1 | MME 286/4885TGFBR1 4721/4885DPP4 891/4885 |
| US-20220177523-A1 | CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF | VIP, LNPEP, TAP1 | MME 286/4885TGFBR1 4721/4885DPP4 891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.